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Background: Presenilin-1 (PS1) is the active component of the amyloid precursor protein cleaving γ-secretase
complex. PS1 protein is a transmembrane protein containing multiple hydrophobic regions which presence in
cerebrospinal fluid (CSF) has not been measured to date. This study assesses whether PS1 and other components
of the γ-secretase complex are present in CSF.
Results: Here, we show that PS1 is present in ventricular post-mortem and lumbar ante-mortem CSF, and plasma as
100–150-kDa hetero-complexes containing both the N- and C-terminal fragments (NTF and CTF) of the protein.
Immunoprecipitation and immunoblotting with different antibodies confirmed the identity of the PS1 species. The
γ-secretase components, APH-1 (anterior pharynx-defective 1) and PEN-2 (presenilin enhancer 2), as well as
presenilin-2 (PS2) fragments, co-exist within these CSF complexes, while nicastrin is not detected. These CSF-PS1
complexes differ from active γ-secretase membrane-complexes, and may represent nonspecific aggregation of the
PS1 protein. Levels of PS1 complexes are increased in CSF samples from autopsy-confirmed Alzheimer’s disease
(AD) cases and were found to be more stable than complexes in CSF from control subjects. Despite similar levels of
total PS1 in CSF from probable AD patients and cognitively normal subjects, an increased proportion of highly
stable PS1 complexes were observed in AD CSF.
Conclusions: Our data suggest that fragments of the PS1 protein present in CSF as complexes may be useful as a
biomarker for AD.
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The major pathological hallmarks of Alzheimer’s disease
(AD), the β-amyloid peptide (Aβ) and the abnormally
hyperphosphorylated protein tau (P-tau), are also recog-
nized biomarkers which have been extensively investigated
(for a review see [1]). However, there is a continuing search
for new cerebrospinal fluid (CSF) biomarkers for use in
clinical diagnosis, especially for the early stages of AD, and
for use in clinical trials.
Other logical AD biomarker candidates are proteins in-
volved in the pathological processing of the large trans-
membrane protein, the amyloid precursor protein (APP),* Correspondence: j.saez@umh.es
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distribution, and reproduction in any mediumleading to β-amyloid formation in the AD brain. The Aβ
polypeptide is generated by processing of APP, through the
successive action of two proteolytic enzymes, β-secretase
and γ-secretase [2]. The major neuronal β-secretase has
been identified as beta-site APP cleaving enzyme 1
(BACE1; [3]). As BACE1 contains a single transmembrane
domain, its presence in CSF is not unexpected [4]. In con-
trast, γ-secretase consists of four essential subunits:
presenilin-1 (or presenilin-2), nicastrin, APH-1 (anterior
pharynx-defective 1), and PEN-2 (presenilin enhancer 2)
[5]. Presenilin-1 (PS1), a transmembrane aspartyl protease,
is the catalytic subunit, and has a nine-transmembrane do-
main topology [6]. A close homologue of PS1, presenilin-2
(PS2), shares a high degree of homology with the PS1 pro-
tein, has functional redundancy and also contains the ac-
tive site of γ-secretase, forming similar but independent
complexes [7].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
García-Ayllón et al. Acta Neuropathologica Communications 2013, 1:46 Page 2 of 13
http://www.actaneurocomms.org/content/1/1/46To our knowledge, the presence of presenilins in CSF
has not been reported to date. In this study we investi-
gated if PS1 is detectable in CSF and if altered levels of
this protein reflect the pathological condition.
Results
PS1 NTF and CTF are present in high molecular mass
complexes in CSF and plasma
PS1 is known to undergo endoproteolytic cleavage as part
of its maturation, generating N- and C-terminal fragments
(NTF and CTF) [8], with very little full-length PS1 detect-
able in brain or cultured cells [9]. To determine the pres-
ence of PS1 in human CSF, we first examined ventricular
post-mortem CSF samples by Western blotting using differ-
ent anti-PS1 NTF and CTF antibodies (a schematic repre-
sentation of PS1 structure and epitopes for antibodies is
represented in Figure 1A). Immunoblotting, using an anti-
PS1 NTF antibody (Calbiochem), revealed predominant
bands of approximately 100 and 150 kDa and only a faint
29-kDa band corresponding to PS1-NTF (Figure 1B). Im-
munoblotting with the PS1-CTF antibody 00/2 detected
the 100–150-kDa complex, and a weak ~20-kDa bandFigure 1 PS1 complexes are detected in human CSF with alternative
anti-PS1 antibodies indicated. (B) Human ventricular post-mortem CSF samples
conditions with the indicated anti-PS1 antibodies. (C) Loss of CSF-PS1 reactivity
antibody from Calbiochem. The stability of CSF-PS1 is also affected after 20 min
samples were also blotted for the homologue PS2 with an anti-CTF antibody (
and nicastrin. Nicastrin was the only γ-secretase partner with a different bandin
the protein, which was weakly detectable in some of the CSF samples tested. T
antibody, as fragments of this size have not been previously demonstrated to
electrophoresis (heating for 5 min at 98°C or 10 min at 50°C) on stability of APH
PEN-2 were only detected after heating at 50°C, while the 130 kDa-kDa nicastri
is not a part of the complexes. Illustrative examples (from 3 different experimencorresponding to PS1-CTF (Figure 1B). The use of alterna-
tive NTF and CTF antibodies confirmed the specificity of
the PS1 signal in CSF samples (Figure 1B). Similar high
molecular mass complexes of PS1, composed at least in
part of both NTF and CTF, have been previously described
in untransfected cells [10]. A similar banding pattern was
obtained for PS2 complexes in CSF using the PS2-CTF
antibody 00/12 (Figure 1C); PS2 fragments having similar
high molecular mass as PS1 [7,11].
Difference in assay conditions, such as the presence of
detergents, can affect the molecular interactions neces-
sary for PS1 complex formation and its subsequent de-
tection [10]. PS1 aggregates have previously been
described as temperature-sensitive [12]. As the denatur-
ation temperature prior to electrophoresis is not stan-
dardized, we determined the effect of sample heating
during preparation on the stability of high molecular
mass PS1 complexes. The high temperature used during
sample preparation for electrophoresis (98°C compared
with 50°C), resulted in an overall loss of PS1 immunore-
activity, the higher molecular mass complexes being the
most severely affected (Figure 1C). These experimentsantibodies. (A) Schematic representation of PS1 with epitopes for the
from non-demented controls (NDC) were blotted under denaturing
in CSF samples heated at 98°C compared to 50°C using the NTF-PS1
utes of heating at 50°C resulting in loss of immunoreactivity. (D) CSF
00/12) and for other subunits of the γ-secretase complexes, APH-1, PEN-2
g pattern, with a 130-kDa band corresponding to the molecular mass of
he ~35-kDa band (*) may correspond to nonspecific binding by the
be positive for nicastrin. (E) Effect of denaturation temperature prior to
-1, PEN-2 and nicastrin. High molecular mass complexes of APH-1 and
n subunit was detected after denaturation at 98°C, indicating that nicastrin
ts).
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handling may influence the stability and detection of PS1
complexes. Studies performed with samples denatured at
98°C can therefore underestimate and fail to detect PS1
complexes. In this study, all analyses performed on PS1
avoided freeze-thaw cycles and denaturation before elec-
trophoresis was conducted at 50°C.
Interestingly, under the conditions used for PS1 com-
plex detection, PEN-2 and APH-1 immunoreactivities
in CSF displayed similar electrophoretic banding pat-
terns. However the traces of nicastrin that were detected
were not part of the high molecular mass presenilin
complexes (Figure 1D). Nicastrin was only reliably
detected when sample preparation for electrophoresis
was performed at 98°C (Figure 1E).Figure 2 Immunoprecipitation of PS1 in human CSF. (A) Ventricular pos
and precipitated proteins (IP) were immunoblotted with PS1-NTF (Calbiochem
immunoblotted with the PS2-CTF antibody 00/12. (B) Lumbar ante-mortem CS
from Thermo Scientific, and precipitated proteins (IP) detected with an NTF-PS
over-expressing PS1 (+) and extracted in the presence of 1% Nonidet P-40/0.5%
non-diseased control subjects. The presence of a ~43 kDa PS1 holoprotein in m
Calbiochem. Comparison of the immunoreactive bands indicates that this 50-k
were also immunoblotted with anti APH-1, PEN-2 or nicastrin antibodies. APH-
Extracts incubated with protein A-Sepharose with an irrelevant rabbit IgG (BouTo further examine the identity of PS1complexes
in human CSF, we performed immunoprecipitation/
Western blot analysis (Figure 2A). Post-mortem CSF
samples were immunoprecipitated using the 98/1 anti-
body, an alternative PS1-NTF antibody which is effective
in immunoprecipitating human PS1 [13]. Western blot
analysis with the PS1-NTF antibody from Calbiochem and
the PS1-CTF antibody 00/2 detected the predominant
100–150-kDa complexes. These bands were not observed
in negative immunoprecipitation controls, including when
an irrelevant rabbit IgG was used (Figure 2A). Consider-
able amounts of the 50-kDa species were detected in PS1
immunoprecipitates using both anti-NTF and CTF anti-
bodies. This species was also detected in NTF-PS1 immu-
noprecipitates from freshly collected ante-mortem lumbart-mortem CSF was immunoprecipitated with the anti-PS1 98/1 antibody,
) or PS1-CTF antibodies (00/2). Precipitated proteins (IP) were
F was immunoprecipitated with NTF-PS1 antibody 98/1 or with antibody
1 antibody from Calbiochem. (C) Extracts from SH-SY5Y cells
Triton X-100 were run in parallel with post mortem CSF samples from
embrane extracts was detected with the NTF-PS1 antibody from
Da band is not the PS1 holoprotein. (D) PS1-precipitated proteins (PS1-IP)
1 and PEN-2, but not nicastrin were detected in PS1 immunoprecipitates.
nd IgG), were analyzed in parallel as negative controls.
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rodimers probably arise from the 100 and 150 kDa com-
plexes during elution at acidic pH, and are therefore not
likely to be post-mortem artefact. The 50-kDa PS1 may
also be derived from NTF and CTF-PS1 aggregation, as
the holoprotein extracted from SH-SY5Y cells transfected
with the human PS1 cDNA had a mass of ~43 kDa
(Figure 2C).
The other known subunits of the γ-secretase complex,
APH-1 and PEN-2, were detected in freshly collected
lumbar samples immunoprecipitated with an alternative
PS1-NTF antibody, indicating that these components are
part of the complexes (Figure 2D). These PS1 complexes
from both post mortem and freshly collected lumbar
CSF also contain PS2 fragments, demonstrating the ex-
istence of mixed complexes of PS1 and PS2 in the CSF
(Figure 2A, 2D).
The CSF-PS1 complexes were further characterized
and compared to human brain γ-secretase membrane
complexes extracted in assay buffer containing 0.5%
dodecylmaltoside [14]. Both CSF and brain extracts were
analyzed by blue native-PAGE (Figure 3A). As expected,
in dodecylmaltoside-solubilized brain membrane frac-
tions, all four γ-secretase subunits co-migrated in several
bands. A weak band immunoreactive for PS1 was identi-
fied at ~250 kDa (open arrowhead). This molecular mass
corresponds to the smallest sized complex in which
active γ-secretase has been observed [15]. However, this
band was not immunoreactive for all the other
γ-secretase subunits. A predominant immunoreactive
band, with a molecular mass of ~450 kDa (closed arrow-
head), was detected with all antibodies. Other high mo-
lecular mass bands, corresponding to large γ-secretase
complexes [15,16], were also immunoreactive for the dif-
ferent γ-secretase subunits, PS1, APH-1 and PEN-2. By
blue native-PAGE, PS1-CSF complexes appeared as a
smear from ~200 to 1000 kDa (Figure 3A). In agreement
with results obtained from SDS-PAGE analysis; only
APH-1 and PEN-2 were present in these CSF-PS1 com-
plexes (Figure 3A). The interpretation of results from
blue native-PAGE analysis of membrane protein com-
plexes is tricky, especially for the limitations of these
methods of size determination by comparison with the
mobilities of hydrophilic molecular mass markers.
Previous studies have also utilized gradient centrifuga-
tion to characterize PS1 complexes [10]. PS1 complexes
were further characterized in lumbar CSF samples and
dodecylmaltoside-solubilized brain membrane fractions
by fractionation on sucrose density gradients containing
the detergent Brij 97 (Figure 3B).
The majority of the PS1 solubilized from human brain
in presence of dodecylmaltoside accumulated close to
the alkaline phosphatase marker (molecular mass ~140-
160 kDa), and were resolved as a 29-kDa band byWestern blotting using an NTF-PS1 antibody under de-
naturing conditions. Brain-PS1 complexes were also
identified in denser fractions, close to the sedimentation
rate of catalase (molecular mass ~232 kDa). Interest-
ingly, these large PS1 complexes were resolved as ~50-
kDa heterodimers. However, CSF-PS1 complexes which
sediment close to alkaline phosphatase were resolved as
stable 100-150 kDa complexes, instead of monomeric
NTF-PS1 (Figure 3B). Large CSF-PS1 complexes were
also resolved as ~50-kDa heterodimers, indicating that
these complexes are less stable in the CSF than those
which sediment at 100-150 kDa. APH-1 and PEN-2 were
again identified as components of the CSF-PS1 com-
plexes (Figure 3C).
No measurable γ-secretase activity [17] was detected
in freshly collected lumbar CSF samples from non-
demented subjects (n = 5). These results indicate that
CSF-PS1 complexes differ from the active γ-secretase
complexes found in the brain, and may represent
nonspecific aggregation of PS1 fragments (together with
APH-1 and PEN-2, but not nicastrin) in the CSF.
Soluble PS1 complexes were also detected in human
plasma (Figure 4A), and in mouse CSF and plasma
(Figure 4B). PS1 complexes were mostly absent in CSF
from a PS1 cKO mouse model where PS1 expression
has been selectively eliminated in neurons from the
postnatal forebrain, decreasing brain PS1 levels [18].
However, PS1 complexes were present in serum samples
from these PS1 cKO mice, indicating that CSF and
plasma PS1 complexes have distinct cellular origins.
PS1 levels are increased in AD ventricular post-mortem CSF
To assess whether PS1 levels are altered in AD, we ana-
lyzed ventricular post-mortem CSF for NTF and CTF-PS1
in 10 AD and in 7 NDC samples. The 100 and 150-kDa
complexes were detected with an anti-NTF antibody in all
CSF analyzed (Figure 5A). The immunoreactivity for the
100 + 150 kDa complexes increased by ~325% in AD com-
pared to NDC subjects (p = 0.005). New aliquots of the
same CSF samples were immunoblotted with an anti–
CTF-PS1 antibody (Figure 5B). In good agreement, CTF-
PS1 immunoreactivity for the 100 + 150 kDa complexes
increased by ~320% in AD compared to NDC subjects
(p = 0.002). The minor form of PS1 (29-kDa) was
decreased in AD compared to NDC subjects (~70%;
p = 0.03); while the 20 kDa-band corresponding to
monomeric PS1-CTF was only very weakly detected
and not quantified.
Fractionation on sucrose density gradients followed by
Western blotting under denaturing conditions revealed
that the highly stable 100-150 kDa complexes were more
abundant in AD samples, while less stable complexes that
sediment in denser fractions were mostly detected in NDC
samples. This difference enabled us to define a quotient
Figure 3 Characterization of CSF-PS1 complexes. (A) Brain γ-secretase complexes (frontal cortex from non-diseased control subjects extracted
in buffer containing 0.5% dodecylmaltoside) were analyzed by blue native-PAGE and compared with PS1 complexes isolated from lumbar CSF
samples (NDC cases). Incubation of blots with antibodies for the different γ-secretase subunits confirmed that nicastrin is not present in CSF-PS1
complexes. (B) The same brain extract and CSF samples were also fractionated on 5-20% sucrose density gradients. The fractions (collected from
the top of each tube) were immunoblotted for NTF-PS1 under denaturing conditions with the antibody from Calbiochem. Enzymes of known
sedimentation coefficient, β-galactosidase (G, 16.0S; ~540 kDa), catalase (C, 11.4S; ~232 kDa) and alkaline phosphatase (P, 6.1S; ~140-160 kDa)
were used as internal markers. (C) CSF fractions from sucrose gradients were also blotted for APH-1, PEN-2 and nicastrin. Nicastrin was mostly
undetectable in fractionated CSF samples.
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kDa heterodimers which sediment closer to alkaline phos-
phatase) and unstable complexes (50-kDa complexes
which sediment closer to catalase), allowing us to fully dis-
criminate between the two groups (Figure 5C).Highly stable PS1 complexes are increased in AD lumbar
ante-mortem CSF
We have demonstrated that high molecular mass PS1
complexes are increased in post-mortem AD CSF.
These PS1 complexes were also assessed in lumbar CSF
Figure 4 PS1 complexes are present in human and mouse CSF
and plasma. (A) Plasma samples from NDC subjects were blotted
with an anti-NTF-PS1 antibody (from Calbiochem) with and without
depletion of plasma abundant proteins by immunoaffinity-based
protein subtraction chromatography with IgY microbeads (Seppro™).
(B) CSF and plasma samples from control wild-type (WT) and PS1
conditional knockout mice (cKO) were blotted with an anti-NTF-PS1
antibody. In general, immunoreactivities of the bands corresponding
to PS1 complexes were weak in mouse (or rat, not shown) than in
human samples. PS1 levels are reduced in CSF from PS1 cKO mice,
and unchanged in plasma. PS1 immunoreactivity detected in CSF
from PS1 cKO mice may be due to PS1 expressed in glia and
interneurons. However, it is also highly likely that some nonspecific
binding may occur at 50 kDa (*).
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of classical AD biomarkers displayed elevated CSF T-
tau and P-tau and low levels of Aβ42 in probable AD
samples (Figure 6). As expected, predominant PS1
bands of approximately 100 and 150 kDa were detected
in all cases, although no notable changes were observed
in total PS1 levels between probable AD and NDC sub-
jects (Figure 7A). No detectable amount of the 29-kDa
species was evident in lumbar CSF samples, nor in
immunoprecipitates from lumbar CSF samples (see
Figure 2). Sucrose density centrifugation profiles (de-
termined in 8 of the 12 lumbar CSF cases, for both
the AD and NDC groups, due to limited volumes) re-
vealed a major contribution of the highly stable PS1
complexes in probable AD cases, compared to NDCs
(Figure 7B). Interestingly, the quotient of the PS1 com-
plexes fractionated in the sucrose gradient correlates
with Aβ42 (r = 0.51, p = 0.04) and with P-tau levels
(r = 0.57, p = 0.02). In the NDC group, age trends to
positive correlates with the quotient of the PS1 com-
plexes (n = 8; r = 0.70, p = 0.07).
Levels of full-length BACE1 in CSF
BACE1, the major neuronal β-secretase, together with γ-
secretase, processes APP through the amyloidogenic
pathway [2]. BACE1 activity levels have been found to
increase in AD CSF and it has been identified as a po-
tential diagnostic marker for AD [4,19-21]. It’s has been
assumed that the BACE1 present in CSF is a truncated
soluble form of the originally membrane-bound BACE1,missing the transmembrane and intracellular domains
[22]. However, it’s possible to identify BACE1 in CSF by
Western blotting using an anti-BACE1 antibody which
binds the C-terminal intracellular domain (antibody
D10E5 from Cell Signaling, with antigenic determinant lo-
cated in residues surrounding Asp490 of human BACE1
protein). Using this antibody, we have evaluated BACE1
levels by Western blotting in the same set of post-mortem
CSFs. Full-length BACE1 was significantly elevated in AD
patients compared with controls (p = 0.018; Figure 8A).
Full-length BACE1 levels also correlated with PS1 when
the quotient of the PS1 complexes fractionated on su-
crose gradients are considered for all samples (r = 0.95,
p < 0.001), or for AD cases (r = 0.93, p < 0.001). No
change was observed in full-length BACE1 levels evalu-
ated in lumbar CSF from probable AD and control sub-
jects (Figure 8B).Discussion
To our knowledge, the possibility that PS1 can be assessed
in the CSF has thus far not been considered. Here, we
demonstrate that heterodimeric complexes composed of
NTF and CTF PS1 are detectable in CSF. To date, the
presence of soluble CTF-PS1 has only been demonstrated
in culture medium of primary neurons and HEK cells [23].
The majority of mature brain PS1 protein is present as
proteolytic NTF- and CTF-PS1 fragments [8]. The exist-
ence of 100–150-kDa complexes containing both endogen-
ous NTF and CTF-PS1 has only previously been described
in cultured cells [10]. PS1 exhibiting higher molecular
mass bands in SDS-PAGE, has also been described in cel-
lular models over-expressing the protein [24,25]. These
high molecular mass bands of PS1 were detected by alter-
native anti-NTF and CTF-PS1 antibodies, confirming that
heterodimers contain both PS1 fragments. Triton X-100, a
common detergent frequently used to extract and solubil-
ise membrane bound proteins, disassembles the 100–150-
kDa complexes [10], and these PS1 heterodimeric species
have therefore been mischaracterized in the many previous
studies. The sensitivity of these complexes to high temper-
atures during sample preparation may contribute to its
mischaracterization. The presence of the minor 29-kDa
NTF and 20-kDa CTF species was only clearly detectable
in post-mortem CSF, where artefacts are likely to appear.
Similarly, the 50-kDa species was only resolved as a major
PS1 band in immunoprecipitates after elution at acid pH.
Ultracentrifugation in sucrose density gradients con-
taining the detergent Brij 97 confirms the existence of
stable complexes of 100–150-kDa, and also of large com-
plexes which sediment in regions closer to 200 and
250 kDa. These large complexes are unstable and resolve
as 50-kDa components during electrophoresis under de-
naturing conditions.
Figure 5 PS1 stable complexes are increased in AD post-mortem CSF. (A) Representative blot of NTF-PS1 in post-mortem CSF samples from
10 AD (open circles) and 7 NDC controls (closed circles). The densitometric quantification of the accumulative immunoreactivity from the sum of the
higher molecular mass PS1 complex (100 + 150 kDa) is shown. (B) Immunodetection and densitometric quantification of higher molecular mass PS1
complex (100 + 150 kDa) from CSF samples blotted with an anti-CTF-PS1 antibody. Dashed lines represent arbitrary cutoffs that maximally discriminated
between AD and NDC groups. (C) PS1 complexes in 4 (of 7) NDC (closed circles) and 8 (of 10) AD CSF samples (open circles) were fractionated on 5-20%
sucrose density gradients. The fractions (collected from the top of each tube) were immunoblotted for NTF-PS1 under denaturing conditions with the
antibody from Calbiochem. Enzymes of known sedimentation coefficient, β-galactosidase (G, 16.0S; ~540 kDa), catalase (C, 11.4S; ~232 kDa) and alkaline
phosphatase (P, 6.1S; ~140-160 kDa) were used as internal markers. Representative blots are shown. A quotient between highly stable complexes
(100 + 150 kDa immunoreactive bands sediment closer to alkaline phosphatase, fractions 2-7) and unstable complexes (50-kDa immunoreactive bands
sediment closer to catalase, fractions 8-12) was defined and represented. Dashed lines represent an arbitrary cutoff that maximally discriminated between
AD and NDC groups. The data represent the means (in arbitrary units) ± SEM. *Significantly different (p< 0.05) from the NDC group, as assessed by the
Mann-Whitney U test.
García-Ayllón et al. Acta Neuropathologica Communications 2013, 1:46 Page 7 of 13
http://www.actaneurocomms.org/content/1/1/46γ-Secretase exists on the plasma membrane as an in-
tact complex composed of its subunit components
[15,26], at a stoichiometry of presenilin:PEN-2:nicastrin:
APH-1, 1:1:1:1 [27]. However, PS1 can associate intra-
molecularly to form higher order complexes [28], where
nicastrin, APH-1 and PEN-2 do not seem to be required
for its hetero- and homodimerization [29]. Interestingly,
our studies have identified APH-1 and PEN-2, but notFigure 6 Levels of classical AD biomarkers in lumbar CSF. Box plot of
circles) and the 12 NDC controls (closed circles). Means ± SEM are shown. Mnicastrin in the PS1-complexes. γ-Secretase activity de-
pends on the presence of all four components of the
complex, including nicastrin [30,31]. As we were unable
to detect γ-secretase activity in human CSF, PS1 com-
plexes in CSF are therefore likely to be the result of
nonspecific aggregation of the protein. PS1-CSF com-
plexes appeared as a smear (from ~200 to 1000 kDa)
and not as defined complexes on blue native-PAGE. PS2CSF levels of Aβ42, T-tau and P-tau for the 12 probable AD cases (open
ann-Whitney U test, *p < 0.05, **p < 0.01.
Figure 7 Stable PS1 complexes are increased in AD ante-mortem CSF. (A) Representative blot and densitometric quantification of the
accumulative immunoreactivity from the sum of higher molecular mass PS1 complex (100 + 150 kDa) in lumbar CSF samples from 12 AD (open
circles) and 12 NDC controls (closed circles). (B) Eight of the 12 cases available from both the AD and NDC groups were also fractioned into 5-20
% sucrose density gradients, and blotted with the NTF-PS1 antibody under denaturing conditions. Internal markers were β-galactosidase (G),
catalase (C) and alkaline phosphatase (P), as in Figure 5. In the right panel the individual values for the quotient between highly stable complexes
(100 + 150 kDa immunoreactive bands sediment at fractions 2-7) and unstable complexes (50 kDa immunoreactive bands sediment at fractions
8-12) are shown. *Significantly different (p < 0.05) from the NDC group, as assessed by Mann-Whitney U test.
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secretase complexes in cell membranes, and PS2 does
not co-precipitate with PS1 fragments in membrane ex-
tracts [7,32]. We were able to demonstrate that frag-
ments of PS2 are bound to the same PS1 complexes in
CSF. As presenilins are proteins with large numbers of
hydrophobic regions, presenilin fragments may be highly
unstable in CSF, and spontaneously form complexes. In-
deed, like many membrane proteins, PS1 has exhibited a
tendency to aggregate under non-native conditions
[11,12]. Thus, in normal conditions, the amount of free
CTF and NTF in CSF should be very low as PS1 pre-
dominantly exists as complexes. Preliminary analysis in-
dicates that PS1 complexes do not contain some of the
abundant CSF proteins known to bind hydrophobic pro-
teins (e.g., albumin). Further characterization of these
complexes is yet to be conducted. The possibility that
other proteins, such as Aβ, may also be part of the PS1
complex needs to be addressed. Similarly, the source
and mechanism of how PS1 appears in CSF is yet to be
determined. Active secretion is unlikely, and it is stillunclear if passive release from brain cells or neuronal
death may be major contributing factors, as recently ob-
served for BACE1 [33].
Stable 100–150-kDa complexes are more abundant in
AD CSF, and this may reflect differences in the hydro-
phobic and ionic properties of PS1 complexes formed
under amyloidogenic conditions. In this context, it is
also remarkable that the 29-kDa NTF, detectable only in
post-mortem CSF, is less abundant in AD samples, indi-
cating that complexes formed under amyloidogenic con-
ditions are particularly stable. Whether PS1 complexes
differ between AD and non-demented subjects requires
further research.
It is likely that molecular aberrations in the AD brain are
reflected in the CSF. Although it cannot be excluded that
the accumulation of Aβ in AD may be partly due to defi-
cient clearance of the peptide, an increase in the generation
of Aβ is plausible. Thus, an increase in activity and/or
levels of β- and γ-secretase protein components should be
expected. These catalytic effectors of β- and γ-secretase are
key enzymes in pathological amyloid processing and the
Figure 8 BACE1 levels in the post-mortem and ante-mortem CSF
samples. (A) Immunodetection and densitometric quantification of
the ~70-kDa immunoreactive BACE1 band from the same post-mortem
CSF cases, AD (open circles) and NDC (closed circles), presented in
Figure 5; and (B) from the same ante-mortem CSF cases, AD (open
circles) and NDC (closed circles), presented in Figure 6. The box blot of
BACE1 levels includes the means of the immunoreactivities (in arbitrary
units) ± SEM (determinations by duplicate). *p < 0.05 significantly
different from NDC group, as assessed by the Student’s t test.
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AD progression. However, it is still unclear if γ-secretase
activity is altered. Reported levels of PS1 in AD brains have
been contradictory. Reports have displayed an increase
[34,35], unchanged levels [36] or even a decrease [37,38] in
levels, compared to levels in non-demented brains. At the
transcriptional level, early reports indicate no differences
between PS1 mRNA levels in AD brain compared to con-
trols [39]. However subsequent research suggests that PS1
mRNA levels in human AD brains are significantly higher
than in those with no dementia [34,40]. Interestingly, we
have shown that Aβ peptide treatment of cultured cells is
able to induce increases in cellular PS1 levels [41], probably
as part of a vicious cycle of Aβ generation.
In our analysis, ventricular post-mortem samples display
large differences in the level of PS1 and the stability of its
complexes. Lumbar CSF samples only display differencesin PS1 complex stability as resolved by sucrose density gra-
dients. Thus, despite high levels of PS1 correlating with an
increased proportion of stable complexes in post-mortem
CSF, results in lumbar CSF suggest that the early and more
significant phenomenon is the change in the dynamics of
the assembly of PS1 complexes, a change that appears to
be a better marker for discriminating between pathological
samples than total PS1 protein levels alone. In any case,
the comparison between the two different sets of CSF sam-
ples is difficult, as the potential existence of artefacts in the
post-mortem samples and the possibility that ventricular
and lumbar CSF samples may differently reflect brain pro-
tein content. Moreover, our collection of lumbar CSF sam-
ples display clear differences for classical AD biomarkers,
but the inherent uncertainty in clinical diagnosis should in-
deed be considered. Although, the more obvious difference
between the CSF collections is that post-mortem CSF re-
flects late stages of the disease, whereas lumbar CSF corre-
sponds to earlier stages of disease in patients. Nonetheless,
CSF PS1, combined with other biomarkers, may constitute
a potential new marker for AD. Furthermore, CSF PS1
may have value as a marker of disease progression or for
monitoring treatment.
As there is still a lack of reliable blood biomarkers for
neurodegenerative disorders, it is important to assess if
levels in plasma of new potential biomarkers correlate
with AD. PS1 is expressed in many peripheral organs as
well as the brain [42,43]. The presence of PS1 complexes
in the serum of PS1 cKO mice, in which PS1 is specific-
ally absent in neurons of the forebrain, while mostly ab-
sent in CSF, suggests that plasma and CSF PS1 may have
distinct cellular origins. Although a small contribution
of brain PS1 to plasma levels cannot be discounted, our
results indicate that PS1 detection in plasma will not be
an efficient marker for brain disorders.
Conclusion
In conclusion, accurate diagnosis of AD during life is es-
sential. Numerous laboratories have reported an increase
in levels of T-tau and P-tau in CSF, but tau is also in-
creased as result of other neurological processes. While
levels of the pathological Aβ42 species are also increased
in the AD brain, the levels in CSF are decreased due
to increasing deposition [44]. These biomarkers have
shown diagnostic accuracy for incipient AD [45], how-
ever, there is still a need to identify additional specific
biochemical markers of AD. Proteins involved in the
pathological processing of amyloid are potential candi-
dates. In this study we demonstrate that CSF PS1 has
potential as a new biomarker. The diagnostic value of
CSF PS1 in the early stages of AD and in other demen-
tias requires further study. In addition, biomarkers are
also important to evaluate drug effects underlying patho-
physiology of the disease [44]. One of the promising AD
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[46,47]. Estimation of PS1 CSF levels may therefore be
useful to challenge the disease-modifying effects of
newer Alzheimer’s therapy.Methods
Patients, PS1 conditional knockout mice and PS1
over-expressing cells
Post-mortem material
Ventricular CSF was obtained post-mortem at the Banco
de Tejidos, Fundación CIEN (Madrid, Spain), Fundación
Hospital de Alcorcón (Madrid, Spain) and Fundación
AlzheimUr (Murcia, Spain). Samples contaminated with
blood were excluded from analysis. CSF was centrifuged at
1000 × g for 15 min to eliminate cells and insoluble mater-
ial prior to biochemical analyses. AD cases [n = 10 (5 fe-
male and 5 male); mean age ± standard error of mean
(SEM); 77 ± 2 years] were selected based on clinical history
of dementia and neuropathological CERAD diagnosis [48].
Samples from age-matched non-demented control (NDC)
cases had no clinical or pathological features of dementia
[n = 7 (2 female and 5 male); 72 ± 3 years]. Only samples
with a post-mortem interval lower than 14 hr were in-
cluded, with no differences between groups.
Microsomal membranes were solubilized from 0.2 g of
human frontal cortex (two NDC cases from Banco de
Tejidos, Fundación CIEN) in buffer containing 0.5%
dodecylmaltoside, 20% glycerol, and 25 mM Bis-Tris/HCl,
pH 7.0, as previously described [14]. γ-Secretase complexes
extracted from membrane preparations were analyzed by
blue native-PAGE.Clinical material
Lumbar CSF samples were obtained from 12 patients
(5 men and 7 women, 71 ± 5 years) with mild-moderate
AD, and 12 healthy volunteers (5 men and 7 women, 66 ±
9 years) from Huddinge University Hospital (Stockholm,
Sweden). All AD patients fulfilled the NINCDS-ADRDA
criteria for “probable” AD [49]. Controls had no history or
symptoms of neurological or psychiatric disorders, or
memory complaints, and had an MMSE score of 28 or
higher. Five non-demented control CSF samples (2 men
and 3 women, 52 ± 7 years) obtained from the Hospital
General Universitario de Elche (Elche, Spain) were analyt-
ically processed within 24-48 hours of collection to avoid
freezing and thawing of the samples.
Plasma samples from five healthy volunteers (76 ±
1 years) were collected in heparinized tubes at the Hos-
pital General Universitario de Elche and separated from
whole blood by centrifugation at 3000 × g for 15 min at
4°C. CSF and plasma samples were aliquoted and frozen
at -80°C until use.Material collected from animals
CSF and plasma samples were also collected from four
3 month-old PS1conditional knockout mice (PS1 cKO)
and five littermates in a C57BL6/129 hybrid background.
In these cKO mice, PS1 expression has been selectively
eliminated in glutamatergic neurons from the postnatal
forebrain at P18, and at 2–3 months of age revealed no
detectable brain PS1 [50]. CSF (4-6 μL) was obtained
by cisternal puncture with a needle inserted in the
suboccipital region through the atlanto-occipital mem-
brane, with a single incision of the subarachnoid space
as previously described [51]. Blood was withdrawn
(0.2 mL) by cardiac puncture with heparinized needles
and syringes. CSF and plasma samples were centrifuged
at 1000 × g for 10 min at 4˚C and the supernatants
stored at -80°C until further analysis.
Material collected from cells
SH-SY5Y cells (800,000 cells/well) were grown in 6 well
plates and transfected with a construct encoding full-
length PS1 [52] (or with the expression plasmid pcDNA3
(Invitrogen), using Lipofectamine 2000® (Invitrogen) ac-
cording to the manufacturer’s instructions.
Western blotting and immunoprecipitation
CSF samples (30-40 μL from human subjects; pooled vol-
ume of 15 μL from 3 mice), or plasma samples (0.5 μL)
were denatured at 50°C for 15 min or alternatively at 98°C
for 5 min for other analyses. For BACE1 analysis CSF sam-
ples were denatured always at 98°C for 5 min. Samples
were resolved by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) under fully reducing con-
ditions. For blue-native gel electrophoresis, samples were
analyzed as previously described [53] and NativeMark™
Unstained Protein Standards (Life Techologies) were used
for molecular weight markers. Alternatively, human plasma
samples were first depleted of highly abundant proteins
using immunoaffinity-based chromatography (Seppro®
IgY14 spin column kit, GenWay Biotech Inc) prior to gel
electrophoresis (25 μg of protein after protein depletion).
The separated proteins were transferred to nitrocellulose
membranes (Schleicher and Schuell Bioscience GmbH)
and probed with PS1 antibodies to N-terminal amino acids
1-65 (Calbiochem), amino acids 21-34 (from Thermo Sci-
entific), amino acids 1-20 (antibody 98/1, [54]); amino acids
303-316 in the loop region of the C-terminal (Sigma), or to
amino acids 301-317 in the loop region of human PS1
(antibody 00/2; [54]). CSF proteins were also probed for
PS2 using the polyclonal rabbit antibody “00/12,” raised to
residues 307–336 of the human PS2 loop domain [55].
BACE1 antibody was from Cell Signaling, nicastrin anti-
body was from Millipore, APH-1, PEN-2 and albumin anti-
bodies were from Sigma. Individual blots were used for the
different antibodies, to eliminate antibody cross-reactivity.
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ary antibody conjugated to horseradish peroxidase and
the signal was detected using ECL Plus detection re-
agent according to the manufacturer’s instructions (GE
Healthcare) in a Luminescent Image Analyzer LAS-
1000 Plus (FUJIFILM). A control CSF sample was used
to normalize the immunoreactive signal. For semi-
quantitative studies, the intensity of immunoreactive bands
was measured by densitometry using Science Lab Image
Gauge v 4.0 software provided by FUJIFILM.
Immunoprecipitations were performed at 4°C by in-
cubating 150 μL of CSF overnight with the primary N-
terminal PS1 antibody 98/1, or alternatively with an
antibody from Thermo Scientific, previously coupled
to protein A-Sepharose by Dimethyl pimelimidate
dihydrochloride (Sigma-Aldrich Co). Precipitated pro-
teins were washed with PBS and eluted with 0.1 M
glycine buffer at pH 2.5. After pH neutralization, su-
pernatants were denatured in Laemmli sample buffer
at 50°C for 15 min and subjected to SDS-PAGE, and
separated proteins were transferred to nitrocellulose
membranes. Blots were incubated with N-terminal
(Calbiochem) and C-terminal (00/2) PS1 antibodies.
Sucrose gradients
PS1 complexes were analysed by ultracentrifugation at
250,000 × g in a continuous sucrose density gradient (5-
20%) for 4 hr at 4°C in a Beckman TLS 55 rotor. CSF ali-
quots (50 μL) were carefully loaded onto the top of the
gradient containing 2 mL of 0.15 M NaCl, 50 mM MgCl2
and 0.5% Brij 97, in 50 mM Tris-HCl (pH 7.4). After cen-
trifugation ~14 fractions were gently collected from the
top of the tubes. Enzyme markers of known sedimentation
coefficient, β-galactosidase, catalase and alkaline phosphat-
ase were used in the gradients to determine the approxi-
mate sedimentation coefficients.Measurement of γ-secretase-mediated peptide cleavage
γ-Secretase activity was assayed as reported elsewhere
[17] using an intramolecularly quenched fluorogenic
peptide probe, in the absence or presence of the γ-
secretase inhibitor L-685,458 (10 μM). Membranes pre-
pared from human brain solubilized in assay buffer
containing 1% CHAPSO were used as positive controls
[17]. Background fluorescence of the peptide probe was
subtracted from all readings.Measurement of T-tau, P-tau and Aβ42by ELISA
Total tau (T-tau), phosphorylated tau (P-tau) and Aβ1-42
(Aβ42) in CSF were determined using specific enzyme-
linked immunosorbent assays (ELISA) (Innogenetics,
Ghent, Belgium).Statistical analysis
All data were analyzed in SigmaStat (Version 2.0; SPSS
Inc.) by Student’s t test (two-tailed) or Mann-Whitney U
test for single pair-wise comparisons and determination of
exact p values. Results are presented as means ± SEM. Cor-
relation between variables was assessed by linear regression
analyses. p values < 0.05 were considered significant.
This study was approved by the ethics committee of
the Miguel Hernandez University and was carried out in
accordance with the Declaration of Helsinki.
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